

SUPPLEMENTARY MATERIALS

Supplementary Table S1. Patient demographics and disease characteristics

Patient characteristics	Patients With CR and PR (n=57) Baseline	Patients With CR and PR (n=31) 12 Month	Patients With CR and PR (n=22) 18 Month
Age, median (range), years	58 (26-76)	60 (44-74)	58 (45-71)
≥65 years, %	28	29	23
ECOG performance status 0/1, %	58/42	55/45	46/54
Central histology review			
Diffuse large B-cell lymphoma, %	74	65	64
Transformed follicular lymphoma, %	25	35	36
Double/triple hits in <i>c-MYC/BCL2/BCL6</i> genes, %	14*	6.4	4.5
Cell of origin:† germinal/nongerminal center B-cell type, %	51/44	52/42	55/36
2/3/4-6 prior lines of antineoplastic therapy, %	40/35/18	42/32/16	41/32/14
IPI ≥2 at study entry, %	68	65	64
Refractory/relapsed to last therapy, %	46/54	52/48	41/59
Prior ASCT, %	54	48	46

ASCT, autologous stem cell transplant; CR, complete response; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic index; PR, partial response.

**c-MYC + BCL2*, n = 7; *c-MYC + BCL2 + BCL6*, n = 1; *c-MYC + BCL6*, n = 4.

†Determined by the Choi algorithm.

Supplementary Table S2. FACT assessment scores (median) for responders

		Baseline, median (SD)			Change from BL Month 3, median (SD)	Change from BL Month 6, median (SD)	Change from BL Month 12, median (SD)	Change from BL Month 18, median (SD)
FACT-Lym	MCID	All patients (N = 108)	Patients With CR/PR (n = 57)	Non-responders (n=51)	Patients With CR/PR (n = 39)	Patients With CR/PR (n = 34)	Patients With CR/PR (n = 30)	Patients with CR/PR (n = 21)
FACT-G TS	3-7	78.8 (16.1)	80.0 (15.2)	71.0 (17.0)	+5.0 (11.9)*	+4.5 (13.9)*	+7.6 (12.2)*	+10.0 (11.1)†
FACT-Lym S	2.9-5.4	44.5 (9.1)	47.0 (9.3)	42.0 (9.0)	+3.0 (7.4)*	+3.0 (7.7)*	+2.5 (6.5)	+3.0 (6.6)*
FACT-Lym TOI	5.5-11	83.0 (19.0)	87.5 (18.3)	74.0 (19.5)	+4.0 (14.5)	+7.0 (15.5)*	+6.0 (15.6)*	+6.0 (13.6)*
FACT-Lym TS	6.5-11.2	122.0 (24.0)	126.5 (22.8)	108.3 (25.1)	+7.0 (17.0)*	+8.3 (20.3)*	+9.2 (17.9)*	+12.0 (16.1)†

+Indicates the means reported are positive changes from baseline.¹⁻⁴

BL, baseline; CR, complete response; FACT-G TS, FACT-General Total Score; FACT-Lym, Functional Assessment of Cancer Therapy-Lymphoma; FACT-Lym S, FACT-Lymphoma Score; FACT-Lym TOI, FACT-Lymphoma Trial Outcome Index; FACT-Lym TS, FACT-Lymphoma Total Score; MCID, minimal clinically important difference; PR, partial response; SD, standard deviation.

*Indicates that the clinical meaningful improvement in HRQoL is greater than MCID lower limit.

†Indicates that clinical meaningful improvement in HRQoL is greater than MCID upper limit.

Supplementary Table S3. FACT-Lym assessment scores for all patients

		Baseline, mean (SD)	Change from BL Month 3, mean (SD)	Change from BL Month 6, mean (SD)	Change from BL Month 12, mean (SD)	Change from BL Month 18, mean (SD)
FACT-Lym	MCID	All patients (N = 108)	All patients (n = 47)	All patients (n = 34) [‡]	All patients (n = 30) [‡]	All patients (n = 21) [‡]
FACT-G TS	3-7	77.0 (16.1)	+4.3 (12.5)*	+5.8 (13.9)*	+6.3 (12.2)*	+10.0 (11.1) [†]
FACT-Lym S	2.9-5.4	44.4 (9.1)	+1.9 (8.6)	+3.0 (7.7)*	+3.7 (6.5)*	+3.1 (6.6)*
FACT-Lym TOI	5.5-11	82.0 (19.0)	+4.0 (15.9)	+6.2 (15.5)*	+6.8 (15.6)*	+9.2 (13.6)*
FACT-Lym TS	6.5-11.2	121.2 (24.0)	+6.4 (19.1)	+8.6 (20.3)*	+9.6 (17.9)*	+13.1 (16.1) [†]

+Indicates the means reported are positive changes from baseline.¹⁻⁴

BL, baseline; CR, complete response; FACT-G TS, FACT-General Total Score; FACT-Lym, Functional Assessment of Cancer Therapy-Lymphoma; FACT-Lym S, FACT-Lymphoma Score; FACT-Lym TOI, FACT-Lymphoma Trial Outcome Index; FACT-Lym TS, FACT-Lymphoma Total Score; MCID, minimal clinically important difference; PR, partial response; SD, standard deviation.

*Indicates that the clinical meaningful improvement in HRQoL is greater than MCID lower limit.

[†]Indicates that clinical meaningful improvement in HRQoL is greater than MCID upper limit.

[‡]All patients are clinical responders (CR/PR).

Supplementary Table S4. SF-36 assessment scores (median) for responders

		Baseline, median (SD)			Change from BL Month 3, median (SD)	Change from BL Month 6, median (SD)	Change from BL Month 12, median (SD)	Change from BL Month 18, median (SD)
SF-36	MCID	All patients (N = 108)	Patients With CR/PR (n = 56)	Non- responders (n=52)	Patients With CR/PR (n = 42)	Patients With CR/PR (n = 38)	Patients With CR/PR (n = 31)	Patients with CR/PR (n = 22)
Bodily pain	3	74.0 (27.1)	74.0 (27.4)	72.0 (26.9)	0.0 (27.9)	0.0 (30.8)	0.0 (28.2)	0.0 (27.0)
General health	2	47.0 (23.3)	47.0 (24.3)	52.0 (22.2)	+13.5 (15.9)*	+10.0 (19.0)*	+5.0 (20.9)*	+6.0 (19.8)*
Mental health	3	75.0 (18.9)	75.0 (18.5)	75.0 (19.2)	0.0 (16.3)	0.0 (14.8)	0.0 (14.7)	0.0 (14.0)
Physical functioning	3	75.0 (26.7)	72.5 (28.0)	75.0 (25.5)	0.0 (23.8)	0.0 (29.8)	0.0 (28.2)	+2.5 (32.9)
Role- emotional	4	91.7 (30.0)	91.7 (32.8)	87.5 (26.8)	0.0 (30.3)	0.0 (29.4)	0.0 (34.7)	0.0 (35.1)
Role- physical	4	50.0 (32.0)	62.5 (34.0)	50.0 (29.8)	0.0 (37.5)	+6.3 (35.1)*	+6.3 (37.4)*	+6.3 (40.1)*
Social functioning	4	75.0 (27.8)	81.3 (26.8)	75.0 (28.8)	0.0 (27.8)	0.0 (33.3)	+12.5 (29.0)*	+12.5 (29.8)*
Vitality	3	56.3 (23.6)	59.4 (24.0)	50.0 (23.3)	+6.3 (23.4)*	+6.3 (24.1)*	+6.3 (23.9)*	+12.5 (24.1)*
Physical health TS	3	43.4 (9.2)	45.6 (9.9)	43.1 (8.4)	+1.3 (9.1)	+1.8 (11.1)	1.3 (10.5)	+3.9 (10.6)*
Mental health TS	3	50.6 (10.5)	51.9 (10.0)	49.7 (11.1)	+0.7 (9.3)	+1.9 (8.5)	1.1 (9.6)	+2.1 (9.9)

+Indicates the means reported are positive changes from baseline.¹⁻⁴

BL, baseline; CR, complete response; MCID, minimal clinically important difference; PR, partial response; SD, standard deviation; SF-36, Short Form 36 Health Survey Version 2; TS, total score.

*Indicates that the clinical meaningful improvement in HRQoL is greater than MCID.

Supplementary Table S5. SF-36 assessment scores for all patients

		Baseline, mean (SD)	Change from BL Month 3, mean (SD)	Change from BL Month 6, mean (SD)	Change from BL Month 12, mean (SD)	Change from BL Month 18, mean (SD)
SF-36	MCID	All patients (N = 108)	All patients (n = 46)	All patients (n = 35) [‡]	All patients (n = 30) [‡]	All patients (n = 21) [‡]
Bodily pain	3	69.4 (27.1)	+0.3 (22.1)	+5.3 (31.5)*	+0.3 (27.2)	+3.5 (27.7)*
General health	2	52.1 (23.3)	+5.2 (23.0)*	+9.9 (19.8)*	+7.0 (21.1)*	+11.0 (18.7)*
Mental health	3	72.8 (18.9)	-1.4 (17.3)	+1.1 (14.6)	+2.3 (14.8)	+0.5 (14.0)
Physical functioning	3	67.1 (26.7)	-1.6 (24.3)	+4.3 (29.7)*	+5.3 (28.6)*	+10.0 (33.3)*
Role- emotional	4	75.2(30.0)	-2.7 (28.0)	+8.3 (28.5)*	+5.8 (35.3)*	+5.0 (35.4)*
Role- physical	4	44.3 (9.2)	+1.1 (34.3)	+8.5 (32.46)*	+8.5 (32.5)*	+9.9 (39.8)*
Social functioning	4	71.1 (27.8)	-1.4 (28.9)	+8.6 (34.0)*	+12.1 (28.7)*	+19.6 (29.7)*
Vitality	3	54.3 (23.6)	+0.7 (21.6)	+6.1 (24.6)*	+6.9 (23.9)*	+10.4 (23.5)*
Physical health TS	3	44.3 (9.17)	+0.9 (9.4)	+2.8 (11.1)	+1.9 (10.5)	+4.3 (10.6)*
Mental health TS	3	48.1 (10.5)	-0.9 (9.5)	+2.3 (8.7)	+2.9 (9.8)	+2.3 (9.8)

+Indicates the means reported are positive changes from baseline.¹⁻⁴

BL, baseline; CR, complete response; MCID, minimal clinically important difference; PR, partial response; SD, standard deviation; SF-36, Short Form 36 Health Survey Version 2; TS, total score.

*Indicates that the clinical meaningful improvement in HRQoL is greater than MCID.

[‡]All patients are responders (CR/PR).

REFERENCES

1. Carter GC, Liepa AM, Zimmermann AH, Morschhauser F. Validation of the functional assessment of cancer therapy–lymphoma (FACT-LYM) in patients with relapsed/refractory mantle cell lymphoma *Blood*. 2008;112(11):2376.
2. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: Validity and first look at minimum important differences in IPF. *Respir Med*. 2010;104(2):296-304.
3. Tam CS, Waller EK, Jaeger U, et al. Prolonged improvement in patient reported quality of life following tisagenlecleucel infusion in adult patients with relapsed/refractory diffuse large B-cell lymphoma: 19-month follow-up of the JULIET study. Presented at Transplantation and Cellular Therapy Meeting; February 20-24, 2019; Houston, TX. Poster 251.
4. Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. *Health Qual Life Outcomes*. 2003;1(1):79.